Peripheral mAb injection may also be assessed given a recent publication describing the beneficial effects of systemically administered BDNF in the R6/2 mouse model of HD [44]; however, the anorexigenic side-effect previously reported for peripherally-administered TrkB ligands will need to be carefully considered. Here, NTRK2 is linked to Huntington disease.